Jim Collins: Cardio Gains

11/22/2002 12:00 am EST


Jim Collins

Chairman and CEO, Insight Capital Research & Management, Inc.

"The market has exhibited several signs that it has hit a bottom," says Jim Collins, editor of Listed Insight. The service follows a proprietary system of isolating stocksfrom among all American Exchange and New York Exchange listed issueswith strong earnings momentum and relative strength. Here, the advisor recommends a cardiovascular products manufacturer.

"Boston Scientific (BSX NYSE) is a developer of less-invasive medical devices. Its cardiovascular unit focuses on technology for interventional cardiology and peripheral vascular and neurovascular procedures. The firm's endosurgery unit focuses on oncology, urology, and gynecology procedures. Its products are generally used for enlarging narrowed blood vessels to prevent heart attack and stroke, opening obstructions for patients suffering from cancer, and mapping electrical problems in the heart. For the third quarter, the company posted net income of $161 million compared to $58 million a year ago. The stock remains near its 52-week high of $39.26. The stock receives an A rating for accumulation/distribution and has a relative strength rating of 97."

Related Articles on